January 20, 2017
Takeda Pharmaceutical will collaborate with US biotech Ovid Therapeutics on the development and commercialization of TAK-935, the Japanese giant’s proprietary compound being developed for rare pediatric epilepsies, the two companies said on January 19. TAK-935 is a novel, potent and...read more